Roger Inhorn

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

JAK2 Associates with the β _c Chain of the Receptor for Granulocyte-Macrophage Colony-Stimulating Factor, and Its Activation Requires the Membrane-Proximal Region

Frederick W. Quelle, Noriko Sato, Bruce A. Witthuhn et al. · Molecular and Cellular Biology · 1994 · 87 citations

Life Sciences, Immunology, Molecular Biology +16

The Murine <i>DUB-1</i> Gene Is Specifically Induced by the βc Subunit of the Interleukin-3 Receptor

Miklos Pless, Roger Inhorn, Bernard Mathey-Prévôt et al. · Molecular and Cellular Biology · 1996 · 55 citations · Full text

Life Sciences, Molecular Biology, Molecular Genetics +15

A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer

Denise A. Yardley, Howard A. Burris, N. W. Peacock et al. · Breast Cancer Research and Treatment · 2010 · 27 citations

Medicine, Oncology, Pharmaceutics +17

TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer

Denise A. Yardley, Edward Arrowsmith, Brooke Daniel et al. · Breast Cancer Research and Treatment · 2017 · 27 citations

Medicine, Oncology, Pharmacology +14